Tenecteplase

(TNKase®)

Tenecteplase

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 50 mg)
Drug ClassTissue plasminogen activators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Tenecteplase (TNKase) is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
  • Information was derived from 15 systematic reviews and meta-analyses.
  • Both tenecteplase and alteplase show comparable outcomes in improving clinical endpoints such as early neurological improvement, excellent functional outcome, and recanalization rates post-treatment in AIS patients.
  • The effectiveness of tenecteplase appears dose-dependent, with the 0.25 mg/kg dosage frequently cited as potentially more efficacious compared to alteplase in achieving excellent functional outcomes at three months.
  • Studies report no significant differences between tenecteplase and alteplase in terms of safety outcomes like symptomatic intracranial hemorrhage and mortality rates.
  • In patients presenting with acute tandem occlusions, tenecteplase's safety and efficacy were comparable to alteplase; however, incidents of any intracranial hemorrhage were more frequent with tenecteplase.
  • Synthesized evidence suggests that tenecteplase offers a viable alternative to alteplase for treatment within 4.5 hours of symptom onset due to its pharmacokinetic profile, favoring single bolus administration, which might offer logistical benefits over alteplase.
  • Tenecteplase stands out as a promising agent, mirroring or surpassing alteplase under certain clinical scenarios, emphasizing the importance of an optimal dosing strategy.

Product Monograph / Prescribing Information

Document TitleYearSource
TNKase (tenecteplase) Prescribing Information.2024Roche Group, South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials.2024Annals of Medicine
Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies.2024Journal of Neurology
Tenecteplase versus alteplase in acute ischemic stroke: a systematic review and meta-analysis.2024Annals of Neurosciences
Efficacy and safety outcomes of Tenecteplase versus Alteplase for thrombolysis of acute ischemic stroke: a meta-analysis of 9 randomized controlled trials.2024Journal of the Neurological Sciences
Intravenous thrombolysis with tenecteplase versus alteplase combined with endovascular treatment of anterior circulation tandem occlusions: a pooled analysis of ETIS and TETRIS.2024European Stroke Journal
Tenecteplase vs. alteplase for treatment of acute ischemic stroke: a systematic review and meta-analysis of randomized trials.2023Frontiers in Neurology
Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials.2023Frontiers in Neurology
Tenecteplase vs. alteplase for intravenous thrombolytic therapy of acute ischemic stroke: a systematic review and meta-analysis.2023Neurology and Therapy
The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials.2023Journal of Thrombosis and Thrombolysis
Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: a pairwise and network meta-analysis of randomized controlled trials.2023Journal of the Neurological Sciences
Different dosing regimens of tenecteplase in acute ischemic stroke: a network meta-analysis of the clinical evidence.2022European Stroke Journal
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review.2022International Journal of Emergency Medicine
Tenecteplase in pulmonary embolism patients: a meta-analysis and systematic review.2022Frontiers in Medicine
Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis.2022Journal of Neurology
Tenecteplase for thrombolysis in stroke patients: systematic review with meta-analysis.2021The American Journal of Emergency Medicine

Clinical Practice Guidelines